Trials / Sponsors / Global Blood Therapeutics

Global Blood Therapeutics

Industry · 9 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Condition Cardio-pulmonary Function	Phase 1	2016-12-01
Completed	Single-Dose PK Study of GBT440 in Subjects With Renal Impairment Renal Impairment	Phase 1	2016-11-01
Terminated	Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest Idiopathic Pulmonary Fibrosis, Hypoxemia	Phase 2	2016-11-01
Completed	An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Sickle Cell Disease	Phase 2	2016-08-01
Completed	Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF Idiopathic Pulmonary Fibrosis, Hypoxemia	Phase 2	2016-06-01
Completed	Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Sickle Cell Disease	Phase 1	2015-09-01
Completed	A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Sickle Cell Disease	Phase 1	2015-09-01
Completed	A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects Anemia, Sickle Cell	Phase 1	2015-06-01
Completed	A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sic Healthy Subjects, Sickle Cell Disease	Phase 1	2014-12-01